Overall, marketing and administrative expenses rose 23% in the second quarter, to $1.525 billion. This increase was largely due to the impact of acquisitions, as well as increased marketing and selling expenses in support of key products, primarily Cymbalta and the diabetes care products.
Lilly's U.S. marketing rights for Actos expired in September; however, Lilly will continue to receive royalties from Takeda Pharmaceuticals North America at a declining rate through September 2009. Lilly continues to market the product in many countries outside the U.S. In the second quarter, Actos generated $93.3 million in revenue for Lilly, a 1% increase versus the second quarter of 2006.
On a reported basis, products launched this decade--Alimta, Byetta, Cialis, Cymbalta, Forteo, Strattera, Symbyax, Xigris and Yentreve--collectively grew 61%, to $1.483 billion, and accounted for 32% of total sales, compared with 24% of total sales in the second quarter of 2006.